A recent systematic review and meta-analysis to assess the diagnostic utility, sensitivity, and specificity of 68Ga-PSMA PET in advanced prostate cancer found an improved detection in patients with biochemical recurrence. This evidence concerns the gene FOLH1 and prostate cancer.